Meta-analyses of randomized trials by Sattar et al. [84] have shown that GLP-1 receptor agonists reduced the risk of broad composite kidney outcome, which included factors such as the development of new severely increased albuminuria, a decline in eGFR, a rise in serum creatinine, a progression to kidney failure, or death from kidney disease, as well as the risk of all-cause mortality in T2DM patients. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.